Profitability Metrics

Gross Margin
85.39%
Operating Margin
139.69%
Net Margin
93.67%

Efficiency Metrics

Revenue per Expense Ratio
118,924,762.0
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
139.69%
Income Tax Rate
0.00%
EPS
0.7700000000

Balance Sheet Analysis

Current Ratio
2.72
Cash Ratio
1.06
Working Capital
$32.92M
Debt to Equity
0.66
Debt to Assets
39.69%
Equity Ratio
60.03%

Cash Flow Analysis

Operating Cash Flow Ratio
55.01%
Free Cash Flow Ratio
55.01%
CapEx to Revenue
0.00%
Dividends Paid
$65.80M
Stock Buybacks
$45.00M
Total Shareholder Returns
$110.80M
Cash Position Change
2,020,000,000.0%

Key Takeaways (2023 FY)

  • Revenue declined by 9.0083650956048%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes

Detailed Growth Metrics

Core Performance

Revenue
-9.01%
Net Income
138.82%
EPS
138.89%
Operating Income
54.68%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-77.53%
Operating Cash Flow
-53.79%
Free Cash Flow
-53.79%

Balance Sheet Health

Assets
1.46%
Debt
38,235.69%
Book Value per Share
2.46%
Inventory
0.00%

Shareholder Returns

Dividends per Share
-22.54%
Shares Outstanding
-0.01%

Long Term Trends

3Y Revenue/Share
-10.72%
5Y Revenue/Share
-22.33%
3Y Dividend/Share
-28.29%
5Y Dividend/Share
-34.42%